Jennifer Carver Buys 5,000 Shares of La Jolla Pharmaceutical (LJPC) Stock
La Jolla Pharmaceutical (NASDAQ:LJPC) COO Jennifer Carver purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, January 9th. The shares were acquired at an average cost of $6.17 per share, for a total transaction of $30,850.00. Following the completion of the acquisition, the chief operating officer now owns 7,632 shares of the company’s stock, valued at $47,089.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
LJPC opened at $6.10 on Friday. The stock has a market capitalization of $159.76 million, a P/E ratio of -1.13 and a beta of 1.72. La Jolla Pharmaceutical has a 12 month low of $5.01 and a 12 month high of $41.36.
La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings results on Wednesday, October 24th. The biopharmaceutical company reported ($1.93) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.01) by $0.08. The company had revenue of $3.47 million during the quarter, compared to analysts’ expectations of $3.38 million. As a group, analysts expect that La Jolla Pharmaceutical will post -8 EPS for the current year.
A number of equities research analysts have commented on LJPC shares. BidaskClub cut La Jolla Pharmaceutical from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 9th. Zacks Investment Research raised La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Thursday, September 27th. ValuEngine cut La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a report on Tuesday, October 2nd. Finally, HC Wainwright reissued a “buy” rating and set a $48.00 price target on shares of La Jolla Pharmaceutical in a report on Thursday, October 25th. Five research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. La Jolla Pharmaceutical has a consensus rating of “Hold” and an average target price of $39.67.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.
Further Reading: Day Trading – Risk Worth the Reward?
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.